Fluorescence-guided malignant glioma resections

Current Drug Discovery Technologies

Volumn 9, Issue 4, 2012, Pages 256-267

  Babu, Ranjith ^a   Adamson, David Cory ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aminolevulinic acid; Fluorescein; Fluorescence; Glioma; Indocyanine green; Nanoparticle; Resection

Indexed keywords

EID: 84868036142     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/157016312803305915     Document Type: Article

References (104)

1. CBTRUS, CBTRUS Statistical Report: Primary brain and central nervous system tumors diagnosed in the United States in 2004-2006. 2010, Central Brain Tumor Registry of the United States: Chicago.
2. Stupp R, Roila F. Malignant glioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20 Suppl 4: 126-8.
3. Adamson DC, McLendon RE. Translational pathology of early cancer: Central nervous system. Cancer Biomarkers 2010; 1.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96. (Pubitemid 40349501)
5. Olson JJ, Ryken T. Guidelines for the treatment of newly diagnosed glioblastoma: introduction. J Neurooncol 2008; 89: 255-8.
6. Eljamel S. Photodynamic applications in brain tumors: a comprehensive review of the literature. Photodiagnosis Photodyn Ther 2010; 7: 76-85.
7. Bogaards A, Varma A, Collens SP, et al. Increased brain tumor resection using fluorescence image guidance in a preclinical model. Lasers Surg Med 2004; 35: 181-90. (Pubitemid 39332274)
8. Olivo M, Wilson BC. Mapping ALA-induced PPIX fluorescence in normal brain and brain tumour using confocal fluorescence microscopy. Int J Oncol 2004; 25: 37-45.
9. Stummer W, Novotny A, Stepp H, Goetz C, Bise K, Reulen HJ. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 2000; 93: 1003-13. (Pubitemid 32800611)
10. Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 2006; 7: 392-401.
11. Peng Q, Warloe T, Berg K, et al. 5-Aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 1997; 79: 2282-308. (Pubitemid 27251011)
12. Hinnen P, de Rooij FW, van Velthuysen ML, et al. Biochemical basis of 5-aminolaevulinic acid-induced protoporphyrin IX accumulation: a study in patients with (pre)malignant lesions of the oesophagus. Br J Cancer 1998; 78: 679-82. (Pubitemid 28375603)
13. Hilf R, Havens JJ, Gibson SL. Effect of delta-aminolevulinic acid on protoporphyrin IX accumulation in tumor cells transfected with plasmids containing porphobilinogen deaminase DNA. Photochem Photobiol 1999; 70: 334-40. (Pubitemid 129555882)
14. Gibson SL, Cupriks DJ, Havens JJ, Nguyen ML, Hilf R. A regulatory role for porphobilinogen deaminase (PBGD) in delta-aminolaevulinic acid (delta-ALA)-induced photosensitization? Br J Cancer 1998; 77: 235-42. (Pubitemid 28029540)
15. Krieg RC, Fickweiler S, Wolfbeis OS, Knuechel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem Photobiol 2000; 72: 226-33.
16. Inoue K, Karashima T, Kamada M, et al. Regulation of 5-aminolevulinic acid-mediated protoporphyrin IX accumulation in human urothelial carcinomas. Pathobiology 2009; 76: 303-14.
17. Xia Y, Huang Y, Lin L, Liu X, Jiang S, Xiong L. A comparative study on the enhancement efficacy of specific and non-specific iron chelators for protoporphyrin IX production and photosensitization in HaCat cells. J Huazhong Univ Sci Technolog Med Sci 2009; 29: 765-70.
18. Blake E, Curnow A. The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells. Photochem Photobiol 2010; 86: 1154-60.
19. Gibson SL, Havens JJ, Metz L, Hilf R. Is delta-aminolevulinic acid dehydratase rate limiting in heme biosynthesis following exposure of cells to delta-aminolevulinic acid? Photochem Photobiol 2001; 73: 312-7.
20. Sinha AK, Anand S, Ortel BJ, et al. Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells. Br J Cancer 2006; 95: 485-95. (Pubitemid 44232558)
21. Eljamel MS. Fluorescence image-guided surgery of brain tumors: explained step-by-step. Photodiagnosis Photodyn Ther 2008; 5: 260-3.
22. Hefti M, von Campe G, Moschopulos M, Siegner A, Looser H, Landolt H. 5-aminolevulinic acid induced protoporphyrin IX fluorescence in high-grade glioma surgery: a one-year experience at a single institutuion. Swiss Med Wkly 2008; 138: 180-5.
23. Stummer W, Stocker S, Wagner S, et al. Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 1998; 42: 518-25; discussion 25-6.
24. Nabavi A, Thurm H, Zountsas B, et al. Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study. Neurosurgery 2009; 65: 1070-6; discussion 6-7.
25. Diez Valle R, Tejada Solis S, Idoate Gastearena MA, Garcia de Eulate R, Dominquez Echavarei P, Aristu Mendiroz J. Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in single-center experience. J Neurooncol 2010; 102: 105-13.
26. Stummer W, Tonn JC, Mehdorn HM, et al. Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study. J Neurosurg 2011; 114: 613-23.
27. Pichlmeier U, Bink A, Schackert G, Stummer W. Resection and survival in glioblastoma multiforme: an RTOG recursive partitioning analysis of ALA study patients. Neuro Oncol 2008; 10: 1025-34.
28. Tsugu A, Ishizaka H, Mizokami Y, et al. Impact of the combination of 5-aminolevulinic Acid-induced fluorescence with intraoperative magnetic resonance imaging-guided surgery for glioma. World Neurosurg 2011; 76: 120-7.
29. Sanai N, Snyder LA, Honea NJ, et al. Intraoperative confocal microscopy in the visualization of 5-aminolevulinic acid fluorescence in low-grade gliomas. J Neurosurg 2011; 115: 740-8.
30. Tonn JC, Stummer W. Fluorescence-guided resection of malignant gliomas using 5-aminolevulinic acid: practical use, risks, and pitfalls. Clin Neurosurg 2008; 55: 20-6.
31. Moore GE, Peyton WT. The clinical use of fluorescein in neurosurgery; the localization of brain tumors. J Neurosurg 1948; 5: 392-8.
32. Uzuka T, Takahashi H, Fuji Y. [Surgical strategy for malignant glioma resection with intraoperative use of fluorescein Na]. No Shinkei Geka 2007; 35: 557-62. (Pubitemid 46984293)
33. Murray KJ. Improved surgical resection of human brain tumors: Part I. A preliminary study. Surg Neurol 1982; 17: 316-9. (Pubitemid 12119380)
34. Kabuto M, Kubota T, Kobayashi H, et al. Experimental and clinical study of detection of glioma at surgery using fluorescent imaging by a surgical microscope after fluorescein administration. Neurol Res 1997; 19: 9-16. (Pubitemid 27143654)
35. Kuroiwa T, Kajimoto Y, Ohta T. Development of a fluorescein operative microscope for use during malignant glioma surgery: a technical note and preliminary report. Surg Neurol 1998; 50: 41-8; discussion 8-9.
36. Kuroiwa T, Kajimoto Y, Ohta T. Comparison between operative findings on malignant glioma by a fluorescein surgical microscopy and histological findings. Neurol Res 1999; 21: 130-4. (Pubitemid 29100389)
37. Shinoda J, Yano H, Yoshimura S, et al. Fluorescence-guided resection of glioblastoma multiforme by using high-dose fluorescein sodium. Technical note. J Neurosurg 2003; 99: 597-603. (Pubitemid 37040427)
38. Shinoda J, Sakai N, Murase S, Yano H, Matsuhisa T, Funakoshi T. Selection of eligible patients with supratentorial glioblastoma multiforme for gross total resection. J Neurooncol 2001; 52: 161-71. (Pubitemid 32691179)
39. Koc K, Anik I, Cabuk B, Ceylan S. Fluorescein sodium-guided surgery in glioblastoma multiforme: a prospective evaluation. Br J Neurosurg 2008; 22: 99-103. (Pubitemid 351161554)
40. Kremer P, Wunder A, Sinn H, et al. Laser-induced fluorescence detection of malignant gliomas using fluorescein-labeled serum albumin: experimental and preliminary clinical results. Neurol Res 2000; 22: 481-9. (Pubitemid 30602552)
41. Ichioka T, Miyatake S, Asai N, et al. Enhanced detection of malignant glioma xenograft by fluorescein-human serum albumin conjugate. J Neurooncol 2004; 67: 47-52. (Pubitemid 38418248)
42. Kremer P, Fardanesh M, Ding R, Pritsch M, Zoubaa S, Frei E. Intraoperative fluorescence staining of malignant brain tumors using 5-aminofluorescein-labeled albumin. Neurosurgery 2009; 64(3 Suppl): 53-60; discussion -1.
43. Sanai N, Eschbacher JM, Hattendorf G, et al. Intraoperative confocal microscopy for Brain Tumors: A Feasibility Analysis in Humans. Neurosurgery 2011; 68: 282-90; discussion 290.
44. Lopez-Saez MP, Ordoqui E, Tornero P, Baeza A, Sainza T, Zubeldia JM, et al. Fluorescein-induced allergic reaction. Ann Allergy Asthma Immunol 1998; 81: 428-30. (Pubitemid 28555532)
45. Yannuzzi LA, Rohrer KT, Tindel LJ, et al. Fluorescein angiography complication survey. Ophthalmology 1986; 93: 611-7. (Pubitemid 16086713)
46. Kwan AS, Barry C, McAllister IL, Constable I. Fluorescein angiography and adverse drug reactions revisited: the Lions Eye experience. Clin Experiment Ophthalmol 2006; 34: 33-8. (Pubitemid 43379368)
47. Kwiterovich KA, Maguire MG, Murphy RP, et al. Frequency of adverse systemic reactions after fluorescein angiography. Results of a prospective study. Ophthalmology 1991; 98: 1139-42.
48. Jennings BJ, Mathews DE. Adverse reactions during retinal fluorescein angiography. J Am Optom Assoc 1994; 65: 465-71.
49. Matsuura M, Ando F, Fukumoto K, Kyogane I, Torii Y, Matsuura M. [Usefulness of the prick test for anaphylactoid reaction in intravenous fluorescein administration]. Nippon Ganka Gakkai Zasshi 1996; 100: 313-7. (Pubitemid 26125501)
50. Fineschi V, Monasterolo G, Rosi R, Turillazzi E. Fatal anaphylactic shock during a fluorescein angiography. Forensic Sci Int 1999; 100: 137-42. (Pubitemid 29142425)
51. Hitosugi M, Omura K, Yokoyama T, et al. An autopsy case of fatal anaphylactic shock following fluorescein angiography: a case report. Med Sci Law 2004; 44: 264-5. (Pubitemid 39486210)
52. Tanahashi S, Lida H, Dohi S. An anaphylactoid reaction after administration of fluorescein sodium during neurosurgery. Anesth Analg 2006; 103: 503. (Pubitemid 44140682)
53. Dilek O, Ihsan A, Tulay H. Anaphylactic reaction after fluorescein sodium administration during intracranial surgery. J Clin Neurosci 2011; 18: 430-1.
54. Ellis PP, Schoenberger M, Rendi MA. Antihistamines as prophylaxis against side reactions to intravenous fluorescein. Trans Am Ophthalmol Soc 1980; 78: 190-205. (Pubitemid 11035012)
55. Chung YG, Schwartz JA, Gardner CM, Sawaya RE, Jacques SL. Diagnostic potential of laser-induced autofluorescence emission in brain tissue. J Korean Med Sci 1997; 12: 135-42. (Pubitemid 127711464)
56. Bottiroli G, Croce AC, Locatelli D, et al. Brain tissue autofluorescence: an aid for intraoperative delineation of tumor resection margins. Cancer Detect Prev 1998; 22: 330-9. (Pubitemid 28310126)
57. Lin WC, Toms SA, Johnson M, Jansen ED, Mahadevan-Jansen A. In vivo brain tumor demarcation using optical spectroscopy. Photochem Photobiol 2001; 73: 396-402.
58. Croce AC, Fiorani S, Locatelli D, et al. Diagnostic potential of autofluorescence for an assisted intraoperative delineation of glioblastoma resection margins. Photochem Photobiol 2003; 77: 309-18.
59. Toms SA, Lin WC, Weil RJ, Johnson MD, Jansen ED, Mahadevan-Jansen A. Intraoperative optical spectroscopy identifies infiltrating glioma margins with high sensitivity. Neurosurgery 2007; 61: 327-35
60. Yong WH, Butte PV, Pikul BK, et al. Distinction of brain tissue, low grade and high grade glioma with time-resolved fluorescence spectroscopy. Front Biosci 2006; 11: 1255-63. (Pubitemid 43253417)
61. Marcu L, Jo JA, Butte PV, et al. Fluorescence lifetime spectroscopy of glioblastoma multiforme. Photochem Photobiol 2004; 80: 98-103.
62. Butte PV, Fang Q, Jo JA, et al. Intraoperative delineation of primary brain tumors using time-resolved fluorescence spectroscopy. J Biomed Opt 2010; 15: 027008.
63. Butte PV, Mamelak AN, Nuno M, Bannykh SI, Black KL, Marcu L. Fluorescence lifetime spectroscopy for guided therapy of brain tumors. Neuroimage 2010; 54 (Suppl): S125-35.
64. Hansen DA, Spence AM, Carski T, Berger MS. Indocyanine green (ICG) staining and demarcation of tumor margins in a rat glioma model. Surg Neurol 1993; 40: 451-6. (Pubitemid 23348650)
65. Haglund MM, Hochman DW, Spence AM, Berger MS. Enhanced optical imaging of rat gliomas and tumor margins. Neurosurgery 1994; 35: 930-40; discussion 40-1.
66. Haglund MM, Berger MS, Hochman DW. Enhanced optical imaging of human gliomas and tumor margins. Neurosurgery 1996; 38: 308-17. (Pubitemid 26030710)
67. Britz GW, Ghatan S, Spence AM, Berger MS. Intracarotid RMP-7 enhanced indocyanine green staining of tumors in a rat glioma model. J Neurooncol 2002; 56: 227-32. (Pubitemid 34476991)
68. Ferroli P, Acerbi F, Albanese E, et al. Application of intraoperative indocyanine green angiography for CNS tumors: results on the first 100 cases. Acta Neurochir Suppl 2011; 109: 251-7.
69. Hwang SW, Malek AM, Schapiro R, Wu JK. Intraoperative use of indocyanine green fluorescence videography for resection of a spinal cord hemangioblastoma. Neurosurgery 2010; 67(3 Suppl Operative): ons300-3; discussion ons3.
70. Hope-Ross M, Yannuzzi LA, Gragoudas ES, et al. Adverse reactions due to indocyanine green. Ophthalmology 1994; 101: 529-33. (Pubitemid 24100578)
71. Owens SL. Indocyanine green angiography. Br J Ophthalmol 1996; 80: 263-6. (Pubitemid 26090356)
72. Xiao W, Yao N, Peng L, Liu R, Lam KS. Near-infrared optical imaging in glioblastoma xenograft with ligand-targeting alpha 3 integrin. Eur J Nucl Med Mol Imaging 2009; 36: 94-103.
73. Veiseh M, Gabikian P, Bahrami SB, et al. Tumor paint: a chlorotoxin: Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007; 67: 6882-8. (Pubitemid 47105535)
74. Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H. Use of chlorotoxin for targeting of primary brain tumors. Cancer Res 1998; 58: 4871-9. (Pubitemid 28503684)
75. Hockaday DC, Shen S, Fiveash J, et al. Imaging glioma extent with 131I-TM-601. J Nucl Med 2005; 46: 580-6.
76. Hsu AR, Hou LC, Veeravagu A, et al. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in an orthotopic glioblastoma model. Mol Imaging Biol 2006; 8: 315-23. (Pubitemid 44741368)
77. Zhang Z, Li H, Liu Q, et al. Metabolic imaging of tumors using intrinsic and extrinsic fluorescent markers. Biosens Bioelectron 2004; 20: 643-50. (Pubitemid 39445780)
78. Gibbs-Strauss SL, O'Hara JA, Srinivasan S, Hoopes PJ, Hasan T, Pogue BW. Diagnostic detection of diffuse glioma tumors in vive with molecular fluorescent probe-based transmission spectroscopy. Med Phys 2009; 36: 974-83.
79. Nikas DC, Foley JW, Black PM. Fluorescent imaging in a glioma model in vivo. Lasers Surg Med 2001; 29: 11-7. (Pubitemid 32720687)
80. Poon WS, Schomacker KT, Deutsch TF, Martuza RL. Laser-induced fluorescence: experimental intraoperative delineation of tumor resection margins. J Neurosurg 1992; 76: 679-86.
81. Barua S, Rege K. Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small 2009; 5: 370-6.
82. LaRocque J, Bharali DJ, Mousa SA. Cancer detection and treatment: the role of nanomedicines. Mol Biotechnol 2009; 42: 358-66.
83. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34. (Pubitemid 43723979)
84. Medina OP, Zhu Y, Kairemo K. Targeted liposomal drug delivery in cancer. Curr Pharm Des 2004; 10: 2981-9. (Pubitemid 39214006)
85. Feng B, Tomizawa K, Michiue H, Han XJ, Miyatake S, Matsui H. Development of a bifunctional immunoliposome system for combined drug delivery and imaging in vivo. Biomaterials 2010; 31: 4139-45.
86. Pan X, Wu G, Yang W, Barth RF, Tjarks W, Lee RJ. Synthesis of cetuximab-immunoliposomes via a cholesterol-based membrane anchor for targeting of EGFR. Bioconjug Chem 2007; 18: 101-8. (Pubitemid 46145999)
87. Chan WC, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998; 281: 2016-8. (Pubitemid 28475486)
88. Alivisatos AP, Gu W, Larabell C. Quantum dots as cellular probes. Annu Rev Biomed Eng 2005; 7: 55-76. (Pubitemid 41170185)
89. Jackson H, Muhammad O, Daneshvar H, et al. Quantum dots are phagocytized by macrophages and colocalize with experimental gliomas. Neurosurgery 2007; 60: 524-9; discussion 529-30. (Pubitemid 46339198)
90. Muhammad O, Popescu A, Toms SA. Macrophage-mediated colocalization of quantum dots in experimental glioma. Methods Mol Biol 2007; 374: 161-71. (Pubitemid 350183406)
91. Cai W, Shin DW, Chen K, et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett 2006; 6: 669-76.
92. Wang J, Yong WH, Sun Y, et al. Receptor-targeted quantum dots: fluorescent probes for brain tumor diagnosis. J Biomed Opt 2007; 12: 044021.
93. Arndt-Jovin DJ, Kantelhardt SR, Caarls W, de Vries AH, Giese A, Jovin Ast TM. Tumor-targeted quantum dots can help surgeons find tumor boundaries. IEEE Trans Nanobioscience 2009; 8: 65-71.
94. Yu XF, Sun Z, Li M, et al. Neurotoxin-conjugated upconversion nanoprobes for direct visualization of tumors under near-infrared irradiation. Biomaterials 2010; 31: 8724-31.
95. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 2005; 26: 3995-4021. (Pubitemid 40044762)
96. Weissleder R, Stark DD, Engelstad BL, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol 1989; 152: 167-73. (Pubitemid 19024086)
97. Hadjipanayis CG, Machaidze R, Kaluzova M, et al. EGFRvIII antibody-conjugated iron oxide nanoparticles for magnetic resonance imaging-guided convection-enhanced delivery and targeted therapy of glioblastoma. Cancer Res 2010; 70: 6303-12.
98. Meng XX, Wan JQ, Jing M, Zhao SG, Cai W, Liu EZ. Specific targeting of gliomas with multifunctional superparamagnetic iron oxide nanoparticle optical and magnetic resonance imaging contrast agents. Acta Pharmacol Sin 2007; 28: 2019-26. (Pubitemid 350198333)
99. Veiseh O, Sun C, Gunn J, et al. Optical and MRI multifunctional nanoprobe for targeting gliomas. Nano Lett 2005; 5: 1003-8. (Pubitemid 40925409)
100. Kircher MF, Mahmood U, King RS, Weissleder R, Josephson L. A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res 2003; 63: 8122-5. (Pubitemid 37549457)
101. Trehin R, Figueiredo JL, Pittet MJ, Weissleder R, Josephson L, Mahmood U. Fluorescent nanoparticle uptake for brain tumor visualization. Neoplasia 2006; 8: 302-11.
102. Veiseh O, Gunn JW, Kievit FM, et al. Inhibition of tumor-cell invasion with chlorotoxin-bound superparamagnetic nanoparticles. Small 2009; 5: 256-64.
103. Sun C, Veiseh O, Gunn J, et al. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008; 4: 372-9. (Pubitemid 351421268)
104. Wan J, Meng X, Liu E, Chen K. Incorporation of magnetite nanoparticle clusters in fluorescent silica nanoparticles for highperformance brain tumor delineation. Nanotechnology 2010; 21: 235104.